Here’s why Prescient Therapeutics is drawing increasing attention with a ~4x share price surge so far in 2021
ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat...
ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat...
This year, the ASX healthcare index gained a little more than 10% year to date....
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Australia-based clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has completed another action-packed year with a...
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke,...
Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.